The MEAM regimen consisting of ranimustine (MCNU), etoposide (ETP), cytarabine (Ara-C), and melphalan (MEL) is widely used before auto-peripheral blood stem cell transplantation (auto-PBSCT) for malignant lymphoma in Japan. The MEAM regimen generally consists of 200–400 mg/m² for 4 days, but we decided to increase the dosage of Ara-C from the standard to 2 g/m² for 2 days with the aim of increasing drug transferability to the central nervous system. We evaluate the safety and therapeutic efficacy of high-dose Ara-C MEAM therapy.

Methods

The high-dose Ara-C MEAM protocol consisted of MCNU 300 mg/m² on day –7, ETP 200 mg/m² on days –6, –5, –4, –3 and Ara-C 2 g/m² on day –4 –3, and MEL 140 mg/m² on day –2. We retrospectively analyzed 37 cases of malignant lymphoma at our institution between May 2014 and July 2020.

Results

All patients got engraftment and there were no cases of treatment-related mortality. In all cases, the 3-year overall survival (OS) and progression-free survival (PFS) after transplantation were 80.6% and 65.7%, respectively. Twenty-one cases of diffuse large B-cell lymphoma recurrence, for which there is proven usefulness of auto-PBSCT, showed good results after transplantation, with the 3-year OS and PFS after transplantation being 100% and 74.3%, respectively.

Conclusion

The safety and efficacy of high-dose Ara-C MEAM therapy were demonstrated, but the expected therapeutic effect on central nervous system lesions could not be fully evaluated owing to the small number of cases.

CONFLICTS OF INTEREST

None of the authors has a financial interest in the conduct or reporting of the study.

Open Research

DATA AVAILABILITY STATEMENT

The data that support the statistical analysis of this study are available from the corresponding author upon reasonable request.

REFERENCES

1Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995; 333(23): 1540-1545.
10.1056/NEJM199512073332305
CAS PubMed Web of Science® Google Scholar
2Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010; 28(27): 4184-4190.
10.1200/JCO.2010.28.1618
PubMed Web of Science® Google Scholar
3Oliansky DM, Czuczman M, Fisher RI, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of diffuse large B cell lymphoma: update of the 2001 evidence-based review. Biol Blood Marrow Transplant. 2011; 17(1): 20-47.e30.
10.1016/j.bbmt.2010.07.008
PubMed Web of Science® Google Scholar
4Khouri IF, Romaguera J, Kantarjian H, et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol. 1998; 16(12): 3803-3809.
10.1200/JCO.1998.16.12.3803
CAS PubMed Web of Science® Google Scholar
5Tam CS, Bassett R, Ledesma C, et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood. 2009; 113(18): 4144-4152.
10.1182/blood-2008-10-184200
CAS PubMed Web of Science® Google Scholar
6Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013; 369(18): 1681-1690.
10.1056/NEJMoa1301077
CAS PubMed Web of Science® Google Scholar
7Murayama T, Fukuda T, Okumura H, et al. Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04). Int J Hematol. 2016; 103(6): 676-685.
10.1007/s12185-016-1976-4
CAS PubMed Web of Science® Google Scholar
8Magrath I, Adde M, Shad A, et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14(3): 925-934.
10.1200/JCO.1996.14.3.925
CAS PubMed Web of Science® Google Scholar
9Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer. 2006; 106(7): 1569-1580.
10.1002/cncr.21776
CAS PubMed Web of Science® Google Scholar
10Johnson NA, Savage KJ, Ludkovski O, et al. Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival. Blood. 2009; 114(11): 2273-2279.
10.1182/blood-2009-03-212191
CAS PubMed Web of Science® Google Scholar
11Davies A. Double-hit lymphoma: so what? Hematol Oncol. 2019; 37: 19-23.
10.1002/hon.2581
CAS PubMed Web of Science® Google Scholar
12Chen YB, Lane AA, Logan B, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015; 21(6): 1046-1053.
10.1016/j.bbmt.2015.02.005
PubMed Web of Science® Google Scholar
13Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity. Leuk Res. 2011; 35(2): 183-187.
10.1016/j.leukres.2010.07.016
CAS PubMed Web of Science® Google Scholar
14Milpied N, Deconinck E, Gaillard F, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med. 2004; 350(13): 1287-1295.
10.1056/NEJMoa031770
CAS PubMed Web of Science® Google Scholar
15Sugimoto M, Ito S, Mashima K, et al. Retrospective evaluation of the MEAM regimen as a conditioning regimen before autologous peripheral blood stem cell transplantation for lymphoma in two centers with different dosing schedules of melphalan. Ann Hematol. 2016; 95(9): 1513-1519.
10.1007/s00277-016-2740-9
CAS PubMed Web of Science® Google Scholar
16Takasaki H, Hashimoto C, Fujita A, et al. Upfront autologous stem cell transplantation for untreated high-risk diffuse large B-cell lymphoma in patients up to 60 years of age. Clin Lymphoma Myeloma Leuk. 2013; 13(4): 404-409.
10.1016/j.clml.2013.03.003
PubMed Web of Science® Google Scholar
17Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995; 13(3): 588-595.
10.1200/JCO.1995.13.3.588
CAS PubMed Web of Science® Google Scholar
18Martin N, Borchiellini D, Coso D, et al. High-dose chemotherapy with carmustine, etoposide, cytarabine and melphalan followed by autologous stem cell transplant is an effective treatment for elderly patients with poor-prognosis lymphoma. Leuk Lymphoma. 2015; 56(8): 2379-2387.
10.3109/10428194.2014.1001987
CAS PubMed Web of Science® Google Scholar
19Galieni P, Troiani E, Bigazzi C, et al. Modified BEAM as conditioning regimen for lymphoma patients undergoing autologous hematopoietic stem cell transplantation. Bone Marrow Transplant. 2018; 53: 91-93.
10.1038/bmt.2017.206
CAS PubMed Web of Science® Google Scholar
20Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma–a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007; 18(1): 149-157.
10.1093/annonc/mdl327
CAS PubMed Web of Science® Google Scholar
21Schmitz N, Zeynalova S, Nickelsen M, et al. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2016; 34(26): 3150-3156.
10.1200/JCO.2015.65.6520
CAS PubMed Web of Science® Google Scholar
22Oblon DJ, Paul S, Yankee R. Allogeneic transplantation after a conditioning regimen with ifosfamide, carboplatin and etoposide (ICE). Bone Marrow Transplant. 1997; 20(5): 421-423.
10.1038/sj.bmt.1700905
CAS PubMed Web of Science® Google Scholar
23Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant. 2000; 25(12): 1243-1248.
10.1038/sj.bmt.1702433
CAS PubMed Web of Science® Google Scholar
24Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007; 25(30): 4730-4735.
10.1200/JCO.2007.12.5062
CAS PubMed Web of Science® Google Scholar
25Vose JM, Weisenburger DD, Loberiza FR, et al. Late relapse in patients with diffuse large B-cell lymphoma. Br J Haematol. 2010; 151(4): 354-358.
10.1111/j.1365-2141.2010.08330.x
PubMed Web of Science® Google Scholar
26Guglielmi C, Gomez F, Philip T, et al. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled onto the Parma trial. J Clin Oncol. 1998; 16(10): 3264-3269.
10.1200/JCO.1998.16.10.3264
CAS PubMed Web of Science® Google Scholar
27González-Barca E, Boumendil A, Blaise D, et al. Outcome in patients with diffuse large B-cell lymphoma who relapse after autologous stem cell transplantation and receive active therapy. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2020; 55(2): 393-399.
10.1038/s41409-019-0650-x
CAS PubMed Web of Science® Google Scholar
28Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013; 48(3): 452-458.
10.1038/bmt.2012.244
CAS PubMed Web of Science® Google Scholar
29Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106(8): 2912-2919.
10.1182/blood-2005-05-2004
CAS PubMed Web of Science® Google Scholar
30Kawamura K, Hayakawa J, Akahoshi Y, et al. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus and varicella zoster virus diseases after autologous hematopoietic stem cell transplantation. Int J Hematol. 2015; 102(2): 230-237.
10.1007/s12185-015-1810-4
CAS PubMed Web of Science® Google Scholar
31Numata A, Miyamoto T, Ohno Y, et al. Long-term outcomes of autologous PBSCT for peripheral T-cell lymphoma: retrospective analysis of the experience of the Fukuoka BMT group. Bone Marrow Transplant. 2010; 45(2): 311-316.
10.1038/bmt.2009.165
CAS PubMed Web of Science® Google Scholar
32Kato J, Mori T, Yokoyama K, et al. Safety and efficacy of high-dose ranimustine, cytarabine, etoposide and CY (MCVAC) regimen followed by autologous peripheral blood stem cell transplantation for high-risk diffuse large B-cell lymphoma. Bone Marrow Transplant. 2011; 46(7): 923-928.
10.1038/bmt.2010.243
CAS PubMed Web of Science® Google Scholar
33Han LN, Zhou J, Hirose T, Imai Y, Ishiguro T, Chou T. Feasibility and efficacy of high-dose melphalan, cyclophosphamide, etoposide, and dexamethasone (LEED) chemotherapy with or without rituximab followed by autologous stem cell transplantation for aggressive and relapsed non-Hodgkin's lymphoma. Int J Hematol. 2006; 84(2): 174-181.
10.1532/IJH97.06023
CAS PubMed Web of Science® Google Scholar
34Hueso T, Gastinne T, Garciaz S, et al. Bendamustine-EAM versus BEAM regimen in patients with mantle cell lymphoma undergoing autologous stem cell transplantation in the frontline setting: a multicenter retrospective study from Lymphoma Study Association (LYSA) centers. Bone Marrow Transplant. 2020; 55(6): 1076-1084.
10.1038/s41409-020-0783-y
CAS PubMed Web of Science® Google Scholar
35Qualls D, Sullivan A, Li S, et al. High-dose thiotepa, busulfan, cyclophosphamide, and autologous stem cell transplantation as upfront consolidation for systemic non-Hodgkin lymphoma with synchronous central nervous system involvement. Clin Lymphoma Myeloma Leuk. 2017; 17(12): 884-888.
10.1016/j.clml.2017.08.100
PubMed Web of Science® Google Scholar
36Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016; 3(5): e217-e227.
10.1016/S2352-3026(16)00036-3
PubMed Web of Science® Google Scholar
37Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017; 4(11): e510-e523.
10.1016/S2352-3026(17)30174-6
PubMed Web of Science® Google Scholar
38Houillier C, Taillandier L, Dureau S, et al. Radiotherapy or autologous stem-cell transplantation for primary CNS lymphoma in patients 60 years of age and younger: results of the Intergroup ANOCEF-GOELAMS Randomized Phase II PRECIS Study. J Clin Oncol. 2019; 37(10): 823-833.
10.1200/JCO.18.00306
CAS PubMed Web of Science® Google Scholar
39Omuro A, Correa DD, DeAngelis LM, et al. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015; 125(9): 1403-1410.
10.1182/blood-2014-10-604561
CAS PubMed Web of Science® Google Scholar
40Sanders S, Chua N, Larouche JF, Owen C, Shafey M, Stewart DA. Outcomes of consecutively diagnosed primary central nervous system lymphoma patients using the Alberta Lymphoma Clinical Practice Guideline incorporating thiotepa-busulfan conditioning for transplantation-eligible patients. Biol Blood Marrow Transplant. 2019; 25(8): 1505-1510.
10.1016/j.bbmt.2019.04.004
PubMed Web of Science® Google Scholar
41Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013; 19(3): 410-417.
10.1016/j.bbmt.2012.10.029
CAS PubMed Web of Science® Google Scholar
42Kasenda B, Ihorst G, Schroers R, et al. High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group. Leukemia. 2017; 31(12): 2623-2629.
10.1038/leu.2017.170
CAS PubMed Web of Science® Google Scholar
43DeFilipp Z, Li S, El-Jawahri A, et al. High-dose chemotherapy with thiotepa, busulfan, and cyclophosphamide and autologous stem cell transplantation for patients with primary central nervous system lymphoma in first complete remission. Cancer. 2017; 123(16): 3073-3079.
10.1002/cncr.30695
CAS PubMed Web of Science® Google Scholar
44Young PA, Gaut D, Kimaiyo DK, et al. Durable survival outcomes in primary and secondary central nervous system lymphoma after high-dose chemotherapy and autologous stem cell transplantation using a thiotepa, busulfan, and cyclophosphamide conditioning regimen. Clin Lymphoma Myeloma Leuk. 2020; 20(7): 468-479.
10.1016/j.clml.2020.02.009
PubMed Web of Science® Google Scholar
45Cote GM, Hochberg EP, Muzikansky A, et al. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012; 18(1): 76-83.
10.1016/j.bbmt.2011.07.006
CAS PubMed Web of Science® Google Scholar
46Chen YB, Batchelor T, Li S, et al. Phase 2 trial of high-dose rituximab with high-dose cytarabine mobilization therapy and high-dose thiotepa, busulfan, and cyclophosphamide autologous stem cell transplantation in patients with central nervous system involvement by non-Hodgkin lymphoma. Cancer. 2015; 121(2): 226-233.
10.1002/cncr.29023
CAS PubMed Web of Science® Google Scholar
47Yoon DH, Lee DH, Choi DR, et al. Feasibility of BU, CY and etoposide (BUCYE), and auto-SCT in patients with newly diagnosed primary CNS lymphoma: a single-center experience. Bone Marrow Transplant. 2011; 46(1): 105-109.
10.1038/bmt.2010.71
CAS PubMed Web of Science® Google Scholar
48Kondo E, Ikeda T, Izutsu K, et al. High-dose chemotherapy with autologous stem cell transplantation in primary central nervous system lymphoma: data from the Japan Society for Hematopoietic Cell Transplantation Registry. Biol Blood Marrow Transplant. 2019; 25(5): 899-905.
10.1016/j.bbmt.2019.01.020
CAS PubMed Web of Science® Google Scholar
49Schorb E, Fox CP, Fritsch K, et al. High-dose thiotepa-based chemotherapy with autologous stem cell support in elderly patients with primary central nervous system lymphoma: a European retrospective study. Bone Marrow Transplant. 2017; 52(8): 1113-1119.
10.1038/bmt.2017.23
CAS PubMed Web of Science® Google Scholar
50Schorb E, Kasenda B, Ihorst G, et al. High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study. Blood Adv. 2020; 4(14): 3378-3381.
10.1182/bloodadvances.2020002064
CAS PubMed Web of Science® Google Scholar

Volume19, Issue1

February 2023

Pages 136-148

Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study

Abstract

Aim

Methods

Results

Conclusion

CONFLICTS OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Safety and efficacy of high-dose cytarabine MEAM therapy and other treatments for auto-peripheral blood stem cell transplantation: A retrospective comparative study

Abstract

Aim

Methods

Results

Conclusion

CONFLICTS OF INTEREST

Open Research

DATA AVAILABILITY STATEMENT

REFERENCES

References

Related

Information